Is Citius Oncology, Inc. profitable?

Citius Oncology, Inc. is not currently profitable: it reported a net loss of $42.5M over the trailing twelve months.

What is Citius Oncology, Inc.'s earnings per share?

Citius Oncology, Inc.'s diluted EPS over the trailing twelve months is $-0.47.

Where does Citius Oncology, Inc.'s income statement data come from?

Every line is extracted from Citius Oncology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Citius Oncology, Inc. CTOR Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q2 '26	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25
Total revenue	——	——	——	——	——
Total cost of revenue	——	——	——	——	——
Gross profit	——	——	——	——	——
Research and development	$4.11M-33.4%	$6.17M-3.8%	$6.42M-3.3%	$6.64M-2.8%	$6.83M+35.5%
General and administrative	$29.7M+257%	$8.32M-5.3%	$8.78M-21.2%	$11.15M+3.2%	$10.81M+8.6%
Total operating expenses	$48.02M+88.0%	$25.53M+8.6%	$23.52M-7.7%	$25.48M+1.3%	$25.16M+12.4%
Operating income	-$43.52M-94.5%	-$22.38M+4.9%	-$23.52M+7.7%	-$25.48M-1.3%	-$25.16M-40.1%
Interest expense	$296.9K—	——	——	——	——
Other income (expense), net	$1.66M+1,182%	-$153.8K+15.3%	-$181.66K-110%	$1.9M-26.4%	$2.58M-23.7%
Income before income taxes	-$41.95M-85.8%	-$22.58M+4.7%	-$23.7M+7.6%	-$25.64M-1.9%	-$25.16M-12.4%
Income tax expense	$561.51K-46.9%	$1.06M0.0%	$1.06M+12.8%	$936.72K+14.7%	$816.48K+17.3%
Net income	-$42.51M-79.9%	-$23.64M+4.5%	-$24.76M+6.8%	-$26.58M-2.3%	-$25.98M-12.6%
Diluted earnings per share	-$0.47-51.6%	-$0.31+8.8%	-$0.34+10.5%	-$0.38-2.7%	-$0.37-12.1%
EBIT	-$43.52M-94.5%	-$22.38M+4.9%	-$23.52M+7.7%	-$25.48M-1.3%	-$25.16M-40.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Citius Oncology, Inc. profitable?: Citius Oncology, Inc. is not currently profitable: it reported a net loss of $42.5M over the trailing twelve months.
What is Citius Oncology, Inc.'s earnings per share?: Citius Oncology, Inc.'s diluted EPS over the trailing twelve months is $-0.47.
Where does Citius Oncology, Inc.'s income statement data come from?: Every line is extracted from Citius Oncology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.